Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Portfolio Pulse from
Verastem Oncology announced that the FDA has accepted and granted priority review to their New Drug Application for avutometinib in combination with defactinib for treating recurrent KRAS mutant low-grade serous ovarian cancer.
December 30, 2024 | 9:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Verastem Oncology's New Drug Application for avutometinib and defactinib has been accepted by the FDA for priority review, indicating potential accelerated approval for treating recurrent KRAS mutant low-grade serous ovarian cancer.
The FDA's acceptance and priority review of Verastem's NDA suggests a positive regulatory outlook, which could lead to accelerated approval. This is likely to boost investor confidence and positively impact VSTM's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100